Explore Stanford technologies available for licensing:

Researchers at Stanford, the University of Massachusetts and the Chan Zuckerberg Biohub have developed methods to increase or decrease RNA interference target cleavage rates.

Researchers at Stanford have developed a microparticle-based vaccine that in a single shot enables enhanced activation of CD8+ and/or CD4+ T cells to fight against infectious diseases and cancer.

Researchers at Stanford have developed a method of using retinoic acid to treat dilated cardiomyopathy (DCM).

Researchers at Stanford and the Chan Zuckerberg Biohub have discovered cross reactive, broadly neutralizing human antibodies against all serotypes of dengue virus.

Ear infections are a serious condition, especially in children, and represent a $4B market. Otitis media (OM) is when the middle ear becomes inflamed and affects 90% of children worldwide.

Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed PMD (Protect, Modify, Deprotect), an immunofocusing strategy that can be used in vaccine development for the generation of antibodies targeting a specific epitope.

Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed a method for determining infant susceptibility to severe dengue disease through measurement of maternal anti-dengue IgG.

Stanford researchers have developed a technology to better understand the effects of rare genetic variants on an individual's common disease risk.

Stanford researchers in the Deisseroth Lab have discovered molecular targets and brain-circuit dynamics underlying dissociation in the brain.

Researchers at Stanford have developed a simplified 2-D in vitro platform to generate human primordial germ cells (PGCs) from pluripotent stem cells.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an efficacious therapy for patients with life-threatening leukemias, but its use has been hindered by the limited availability of donors with matching HLA. Graft manipulation by removing ??

The inventors have developed a light-driven chloride pump (NpHR or Halo) for temporally precise optical inhibition of neural activity with ordinary yellow light.

Title: A device to photo-stimulate peripheral nervous tissue.

Inventor: Michael Llewellyn, Karl Deisseroth, Scott Delp

Abstract:

Temporally precise, noninvasive control of neural circuitry is a long-sought goal of neuroscientists and biomedical engineers. Stanford University researchers in the laboratory of Dr.

The inventors have identified and developed an archaeal light-driven chloride pump (NpHR) from Natronomonas pharaonis for temporally precise optical inhibition of neural activity. NpHR allows either knockout of single action potentials, or sustained blockade of spiking.